What happened
Teal Health announced a $22 million Series A for the Teal Wand, its FDA-authorized at-home HPV self-collection device. The financing brings the company’s stated total funding to $45 million and is intended to support commercial expansion and coverage partnerships.
Why it matters
Cervical-screening innovation is moving beyond the clinic. The consequential question is whether at-home collection can reach people who are overdue for screening without creating a new affordability or follow-up gap.
What to watch
Coverage, follow-up completion after a positive result, access outside major US markets, and independently published real-world outcomes.
